Edgar Filing: INDEVUS PHARMACEUTICALS INC

Ownership Submission

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

COOPER GLENN L MD

2. Issuer Name and Ticker or Trading Symbol
INDEVUS PHARMACEUTICALS INC [IDEV]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
President and CEO

(Last)

(First)

(Middle)

INDEVUS PHARMACEUTICALS, INC., 33 HAYDEN AVENUE

3. Date of Earliest Transaction (Month/Day/Year)
12/04/2008

(Street)

LEXINGTON, MA 02421

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Stock Option (Right to Buy)

$ 5

12/04/2008

D⁽¹⁾

60,000

⁽²⁾

06/10/2009

Common Stock, $.001 par value per share

60,000

$ 0 ⁽¹⁾

Stock Option (Right to Buy)

$ 5

12/04/2008

A⁽¹⁾

60,000

⁽³⁾

12/10/2010

Common Stock, $.001 par value per share

60,000

$ 0 ⁽¹⁾

60,000

Stock Option (Right to Buy)

$ 6.1875

12/04/2008

D⁽¹⁾

800,000

⁽²⁾

06/10/2009

Common Stock, $.001 par value per share

800,000

$ 0 ⁽¹⁾

Stock Option (Right to Buy)

$ 6.1875

12/04/2008

A⁽¹⁾

800,000

⁽³⁾

12/10/2010

Common Stock, $.001 par value per share

800,000

$ 0 ⁽¹⁾

800,000

Stock Option (Right to Buy)

$ 4.1563

12/04/2008

D⁽¹⁾

360,000

⁽²⁾

06/10/2009

Common Stock, $.001 par value per share

360,000

$ 0 ⁽¹⁾

Stock Option (Right to Buy)

$ 4.1563

12/04/2008

A⁽¹⁾

360,000

⁽³⁾

12/10/2010

Common Stock, $.001 par value per share

360,000

$ 0 ⁽¹⁾

360,000

Stock Option (Right to Buy)

$ 6.1875

12/04/2008

D⁽⁴⁾

70,000

⁽²⁾

06/10/2009

Common Stock, $.001 par value per share

70,000

$ 0 ⁽⁴⁾

I ⁽⁴⁾

Spouse

Stock Option (Right to Buy)

$ 6.1875

12/04/2008

A⁽⁴⁾

70,000

⁽³⁾

06/10/2010

Common Stock, $.001 par value per share

70,000

$ 0 ⁽⁴⁾

70,000

I ⁽⁴⁾

Spouse

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
COOPER GLENN L MD INDEVUS PHARMACEUTICALS, INC. 33 HAYDEN AVENUE LEXINGTON, MA 02421	X		President and CEO

Signatures

GLENN L COOPER MD		12/08/2008
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	All of the reported transactions involved the amendment of outstanding stock options to extend the respective expiration dates from 6/10/2009 to 12/10/2010; such extensions are considered by the Securities and Exchange Commission to be cancellations of the current stock options.
(2)	Prior to the extension of the current stock option, such stock option was fully exercisable.
(3)	This stock option is fully exercisable as of the date of this report.
(4)	Dr. Cooper disclaims all beneficial ownership in these options held by his spouse. All of the reported transactions involved the amendment of outstanding stock options held by Dr. Cooper's spouse to extend the respective expiration dates from 6/10/2009 to 6/10/2010; such extensions are considered by the Securities and Exchange Commission to be cancellations of the current stock options.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.